ARCHIVES

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 36 | October 2, 2009

Download PDF Visit The Full Archive

Related Articles

Two Phase III Afatinib Trials Demonstrate Prolonged Survival

May 30, 2014

Funding Opportunities: Lymphoma Fellowship

June 8, 2001

SPORE Eligibility, Cost Issues Clarified In Addendum To RFA

October 25, 1991

In Brief: Ozols Promoted At Fox Chase; Greenberger Moves To Pittsburgh; ACR Names New Officers

October 8, 1993

President’s Cancer Panel Seeks Ways to Open Grants For More New Ideas

December 19, 1980

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001